MAGP2, Recombinant, Human, 6-His-tag (Microfibril-associated Glycoprotein 2, MAGP-2, Microfibrillar-associated Protein 5, MFAP5, MFAP-5, MP25)

MAGP-2 (Microfibril-associated glycoprotein 2), also called MFAP5 (microfibril associated protein 5) is a secreted, cell-associated 25kD mammalian member of the MFAP family of proteins. Human MAGP-2 cDNA encodes 173aa including a 21aa signal sequence, an RDG motif aa30-32; absent in MAGP-1) and a central cysteine-rich binding domain aa84-140. One potential splice variant shows a 10aa deletion between aa73-82 that includes the only potential glycosylation site. Mature human MAGP-2 shares 80%, 82%, 82%, 84% and 85% aa identity with mouse, rat, bovine, porcine and canine MAGP-2, respectively. Both MAGP-1 and MAGP-2 bind and covalently crosslink fibrillins 1 and 2 through the binding domain, but MAGP-2 has more limited distribution and binds a more limited set of extracellular matrix proteins. However, the MAGP-2 RGD motif binds to the integrin av b3, allowing cell attachment to microfibrils. MAGP-2 is thought to facilitate microfibril assembly and induce elastin fiber formation. Through its binding to EGF repeats, MAGP-2 mediates the metalloproteinase-dependent release of Jagged1 and the metalloproteinase-independent release of Notch extracellular domains. In endothelial cells, MAGP-2 promotes angiogenic sprouting through inhibiting Notch signaling, binding integrin av b3 (which then enhances VEGF signaling), and/or enhancing endothelial cell response to FGF basic and EGF. In ovarian cancer, MAGP-2 expression is associated with cancer cell survival, increased microvessel density, and poor prognosis. Skin MAGP-2 expression is increased in human scleroderma and the tight skin (TSK) mouse; MAGP-2 may contribute to abnormal collagen accumulation in these conditions by increasing the half-life of type I collagen. Fibrillin-1 mutations within the region that binds MAGP-2 can be found in Marfan syndrome.\n\nSource:\nRecombinant corresponding to aa22-173, from human MAGP-2 fused to C-terminal 6-His-tag expressed in mouse myeloma cell line, NSO.\n\nMolecular Weight:\n~18.1kD\n\nBiological Activity:\nMeasured by the ability of the immobilized protein to support the adhesion of BUD-8 human skin fibroblast cells. When 2x104 cells/well are added to Recombinant Human MAGP-2 coated plates (10ug/ml with 100ul/well), ~50-75% will adhere after one hour at 37 degrees C.\n\nEndotoxin: ~1EU/1ug (LAL)\n\nStorage and Stability:\nLyophilized powder may be stored at -20 degrees C. Stable for 12 months at -20 degrees C. Reconstitute with sterile buffer. Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. Reconstituted product is stable for 3 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

M2125-16

Size

50ug

Form

Supplied as a lyophilized powder in PBS. BSA free. Reconstitute with PBS to 0.4mg/ml.

Purity

~95% (SDS-PAGE)

References

1. Gibson, M.A. et al. (1996) J. Biol. Chem. 271:1096. 2. Hanssen, E. et al. (2004) J. Biol. Chem. 279:29185. 3. Segade, F. et al. (2002) J. Biol. Chem. 277:11050. 4. Genbank protein Accession # AAQ18021.5. Gibson, M.A. et al. (1999) J. Biol. Chem. 274:13060. 6. Lemaire, R. et al. (2007) J. Biol. Chem. 282:800. 7. Nehring, L.C. et al. (2005) J. Biol. Chem. 280:20349. 8. Miyamoto, A. et al. (2006) J. Biol. Chem. 281:10089. 9. Albig, A.R. et al. (2008) Microvasc. Res. 76:7. 10. Albig, A.R. et al. (2007) Angiogenesis 10:197. 11. Mok, S.C. et al. (2009) Cancer Cell 16:521. 12. Lemaire, R. et al. (2005) Arthritis Rheumatol. 52:1812. 13. Ito, S. et al. (2006) Am.J. Respir. Cell Mol. Biol. 34:688.